Fig. 1
From: Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
Power to demonstrate a benefit on overall survival. a–c Power at 40, 60, and 80% death rate (maturity), respectively. HR of 0.94, 0.89, 0.81, 0.77, which are estimated to correspond to absolute 3, 6, 12, and 15 months gain in OS (on the basis of a 50 months median OS in control arms12) are highlighted in red
